Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.
Breast Cancer|Triple Negative Breast Cancer
DRUG: Antivascular therapy|DRUG: Chemotherapy
iDFS, invasive disease-free survival, 5 years
DRFS, distant recurrence free survival, 5 years|OS, overall survival, 5 years|AE, adverse effects, 5 years
This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.